Synonyms: CM-4620 | compound I [WO2016138472A1]
Compound class:
Synthetic organic
Comment: CM4620 is an investigational Orai1 inhibitor [3]. It is likely to be compound I as claimed in Calcimedica's patent WO2016138472A1 [3].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Gerasimenko JV, Gryshchenko O, Ferdek PE, Stapleton E, Hébert TO, Bychkova S, Peng S, Begg M, Gerasimenko OV, Petersen OH. (2013)
Ca2+ release-activated Ca2+ channel blockade as a potential tool in antipancreatitis therapy. Proc Natl Acad Sci USA, 110 (32): 13186-91. [PMID:23878235] |
2. Gukovskaya AS, Pandol SJ, Gukovsky I. (2016)
New insights into the pathways initiating and driving pancreatitis. Curr Opin Gastroenterol, 32 (5): 429-435. [PMID:27428704] |
3. Velicelebi G, Stauderman K, Dunn M, Roos J. (2016)
Pancreatitis treatment. Patent number: WO2016138472A1. Assignee: Calcimedica, Inc.. Priority date: 27/02/2015. Publication date: 01/09/2016. |
4. Wen L, Voronina S, Javed MA, Awais M, Szatmary P, Latawiec D, Chvanov M, Collier D, Huang W, Barrett J et al.. (2015)
Inhibitors of ORAI1 Prevent Cytosolic Calcium-Associated Injury of Human Pancreatic Acinar Cells and Acute Pancreatitis in 3 Mouse Models. Gastroenterology, 149 (2): 481-92.e7. [PMID:25917787] |